Ben Beech

Urologic Oncologist @ HHC Tallwood Urology via MSKCC, UAlberta, and UWO | Interested in Uro-Onc and chasing powder days.

[Andrew Vickers @VickersBiostats]

"Due to low sensitivity, PSMA-PET/CT without evidence of nodal disease does not obviate the need for PLND" BUT "PSMA-avid nodal disease portends ... nearly inevitable ... recurrence and radiographic progression, supporting treatment intensification." https://t.co/0p3blERPj2

[Ben Beech @BenBeechMD]

Lucky to have gotten to work with these superstars ⭐🌟✨

The best #tumorboardforlife

[Wesley Yip @WesleyYipMD]

Love catching up with friends at #GU26 and all of their accomplishments. 🌟

My cofellow @CChuMD is already an endowed professor @UCSF 💁🏻‍♀️

Me? When I walk into my own OR, they ask if I’m the new fellow and point at the glove cabinet 🤦🏻‍♂️

[Bernie Bochner, MD @bbmdmsk]

Not true. RC and a thorough PLND cures about 1/3 of node + bladderCA pts with surgery ALONE. S1011 enrolled relatively low risk pts (their control performed 10% better than designed) and expected an unrealistically large benefit from the ePLND (10% ⬆️3 yr RFS)=poor design.

[Ben Beech @BenBeechMD]

Great time catching up with the latest scientific advances, and with friends, colleagues and mentors at #SUO2025

[Carissa Chu @CChuMD]

Dr. Samson Fine takes us through the finer points of GS4 prostate cancer at #SUO2025. Quantification and subtype are important, large cribriform present in patients with metastases after prostatectomy

@rovingatuscap @MSKCancerCenter

[Wesley Yip @WesleyYipMD]

Love attending @UroOnc Annual Meeting, but especially when @UrologyMSK ‘21-23 can make it too @sari_safaa @BenBeechMD @SongJiangUro @CChuMD (missing @drMPerera and Alex Doudt)

[Bernie Bochner, MD @bbmdmsk]

A very sad day learning that a giant in urology passed, Donald G. Skinner MD His impact was profound. His commitment to surgical excellence was only matched by his devotion to pt care and teaching. Simply the best mentor, colleague and friend
RIP Boss
@UroOnc @AmerUrological

[Ben Beech @BenBeechMD]

Such an honour and privilege to have trained under Dr Dalbagni. Great exemplar of excellence and efficiency. Truly one of a kind.

[UrologyMSK @UrologyMSK]

Bittersweet evening to celebrate the career and legacy of Guido Dalbagni a legend in the field of bladder cancer. We wish you luck in your next chapter! @MSKCancerCenter

[Ben Beech @BenBeechMD]

Congrats to all and especially our ⭐ resident Bruce Li @westernuUrology 🇨🇦

[UrologyMSK @UrologyMSK]

We are thrilled to announce our @UroOnc match results! Welcome to @MSKCancerCenter and congratulations to all the other applicants!

[Mithun Kailavasan @Mithun_Kaila]

Our latest EAU MIBC SR on all peri-operative stent strategies during radical cystectomy. Is it time to consider stent-less ? @Uroweb @SUO
https://t.co/R7uBmC5ZD8

[Carissa Chu @CChuMD]

Excited to see our paper in print @EUplatinum: https://t.co/9G6F1Q2Q5y

Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial Carcinoma

[Ben Beech @BenBeechMD]

New paper from our group, with star fellow @Mithun_Kaila. Examining the role of primary RPLND in Seminoma. A chance to cut is a chance to cure?

https://t.co/WORO1noBuj

[Andrew Vickers @VickersBiostats]

"We have completed 7 single-center randomized trials, with several more underway and accruing rapidly, with a total accrual approaching 10,000 ... Only one of these trials was externally funded". https://t.co/L06JZQ63tz

[UroToday.com @urotoday]

5-Year survival outcomes in cisplatin-ineligible patients from #EV103. @DrRosenbergMSK @MSKCancerCenter joins @CaPsurvivorship @DanaFarber discuss the 5-year results from EV-103 Cohort A in advanced urothelial cancer. 🌟 Over 40% alive at 5 yrs (vs ~3% w/ chemo), showcasing potential curative effects of enfortumab vedotin + pembrolizumab! 💡 A game-changer for survival & care. #FullVideo on UroToday > https://t.co/CINcu4pkrq

[Testicular Cancer @TestesCancer]

In this episode of It Takes Balls, Dr. Richard Matulewicz of @MSKCancerCenter @UrologyMSK explores the crucial topic of health-related quality of life in #testicularcancer. He explains how patient-centered outcomes—such as body image, mental health, and fears of recurrence—are reshaping care for a cancer that overwhelmingly affects young men with decades of life ahead of them.

#urology #MensHealth #UroSoMe

Links🧵

[UrologyMSK @UrologyMSK]

Now published in @EurUrolOpen by @UrologyMSK @RichMatulewicz Joel Sheinfeld et al.:

Perioperative Serum MicroRNA 371a-3p and 372-3p Levels in Patients with Clinically Localized Testicular Masses
https://t.co/CEBjoNcBC1

[Ben Beech @BenBeechMD]

Great work on PSMA-PET for clinical staging coming out of the University of Alberta with @NikMookerji and @AdamKinnaird

[Nik Mookerji @NikMookerji]

Our trial is published in JAMA Oncology! @AdamKinnaird

Fluorine-18 PSMA-1007 PET/CT vs Multiparametric MRI for Locoregional Staging of Prostate Cancer

https://t.co/8t26F1lm8y

[Ben Beech @BenBeechMD]

@MoffittGUOnc @LoganZemp Congrats Zemp! Learned so much from you as my Chief Resident back in Edmonton! Not just technique or knowledge, but how to carry yourself and go about your business. Well deserved!

[Ben Beech @BenBeechMD]

Congratulations to Dr Dalbagni! An incredible surgeon and teacher with a wealth of experience and endless energy!

[UrologyMSK @UrologyMSK]

Congratulations to our teacher of the year Guido Dalbagni!

[Ben Beech @BenBeechMD]

@JustinLoloi @MontefioreNYC @EinsteinMed @MontefioreUro Congrats! Well deserved based on our time working together at MSK!